NCL is delighted to welcome Curesponse to our portfolio, a breakthrough cancer precision medicine company. Their platform, cResponse, accurately and quickly predicts a patient’s response to cancer treatment.
The company’s platform, cResponse, is a functional cancer diagnostic which preserves the patient tumour in 3D for up to two weeks, allowing observation of the cancer microenvironment’s response to cancer therapies. The platform provides critical and actionable information for clinicians and patients by suggesting the optimal drug selection for each patient which can potentially save lives, reduce the cost of treatment and aid R&D clinical trials as a companion-diagnostic for pharmaceutical companies.
Current cancer diagnostics base treatment predictions on cancer cells alone when in fact tumor-microenvironment interactions and cancer tissue architecture can yield additional drug resistance with tumour cells being “rescued” or protected by surrounding healthy cells and bacteria. These key findings from which the cResponse technology was born are the work of Dr Straussman of the Weizmann Institute, whose papers demonstrating these effects have been published in Nature and Science. While the platform is undergoing clinical validation in Israeli hospitals, this investment raise will allow scaling the trials to the UK.
The Global Precision Medicine Market size exceeded USD 57 billion in 2019 and is estimated to grow at a CAGR of over 11% between 2020 and 2026. Precision medicine will enable a new era of medicine in which researchers, providers, and patients work together to develop individualized care. Curesponse hopes to meet some of the increasing demand for personalized treatment and add to this market’s commercial success.
“We are looking forward to expanding our clinical validation program into the UK and are very pleased to join forces with the impressive team at NCL Technology Ventures with this opportunity. The last few years have brought significantly greater attention to the importance of personalized medicine in patient care in the UK, and we are collaborating with leading clinical sites in London and throughout England to make this technology available to patients as quickly as possible,” Guy Neev, Curesponse CEO.
“NCL is delighted to have invested in Curesponse as it addresses a high unmet need with brilliant frontier science. It is a welcome addition to our portfolio,” Jonathan Synett, NCL Technology Ventures CIO.
Wishing Curesponse a warm welcome to the UK, our portfolio, and mutual success.
To see the full press release, please visit Yahoo Finance: https://finance.yahoo.com/news/curesponse-secures-6m-series-breakthrough-134300952.html